Does State Medicaid Cover Retatrutide?

Why Retatrutide Is Not on Any State Medicaid Formulary Yet

Retatrutide (LY3437943) remains an investigational compound developed by Eli Lilly. No state Medicaid formulary lists it because the FDA has not granted approval for any indication. In the phase 2 trial published in the New England Journal of Medicine, retatrutide 12 mg produced a 24.2% mean reduction in body weight at 48 weeks compared with 2.1% for placebo (N=338) 1.

The drug works through a novel triple-agonist mechanism, simultaneously activating GLP-1, GIP, and glucagon receptors 2. This sets it apart from dual-agonists like tirzepatide, which targets only GLP-1 and GIP receptors 3. The glucagon receptor component may offer distinct metabolic benefits, including increased energy expenditure and hepatic fat reduction 4.

Until the FDA reviews and approves a New Drug Application for retatrutide 5, no insurer, whether Medicaid, Medicare, or commercial, can add it to a standard formulary. Patients currently access retatrutide only through clinical trials listed on the FDA's trial registry 6.

How State Medicaid Programs Handle GLP-1 Coverage Today

Fewer than half of state Medicaid programs cover GLP-1 receptor agonists specifically for chronic weight management. A 2023 analysis from the Obesity Action Coalition found that only 18 states included at least one anti-obesity medication in their Medicaid preferred drug lists without blanket exclusions 7. Coverage for type 2 diabetes, by contrast, is near-universal: the Medicaid Drug Rebate Program requires participating states to cover most FDA-approved medications, and every approved GLP-1 agonist carries a T2D indication 8.

The disparity exists because the Social Security Act permits states to exclude drugs used for "anorexia, weight loss, or weight gain" from mandatory Medicaid coverage 9. States that do cover anti-obesity medications often impose strict utilization management: prior authorization, step therapy, quantity limits, and periodic re-authorization.

For approved GLP-1s like semaglutide 2.4 mg (Wegovy), the STEP-1 trial (N=1,961) showed 14.9% mean weight loss at 68 weeks versus 2.4% with placebo 10. Even with this evidence, many state Medicaid programs still decline coverage, citing budget constraints. A KFF brief estimated that covering all eligible Medicaid beneficiaries for GLP-1 obesity medications could cost states billions annually 11.

What Prior Authorization for Retatrutide Will Likely Require

No state has published prior authorization criteria for retatrutide because the drug remains unapproved. Based on existing PA requirements for semaglutide and tirzepatide across Medicaid programs, a predictable pattern of criteria will likely apply once retatrutide reaches the market.

Typical state Medicaid PA criteria for GLP-1 anti-obesity agents include:

• BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea) 12
• Documentation of a structured diet and exercise program for 3 to 6 months prior to the request
• Prescriber must be an endocrinologist, obesity medicine specialist, or have prior authorization from a primary care physician with documented training
• Re-authorization every 6 to 12 months demonstrating at least 5% body weight loss from baseline

These thresholds mirror the 2022 American Association of Clinical Endocrinology (AACE) guidelines, which recommend pharmacotherapy for patients with a BMI ≥ 30 or BMI ≥ 25 with complications 13. The Endocrine Society's 2024 clinical practice guideline echoes these thresholds and specifically endorses GLP-1 receptor agonists as first-line pharmacotherapy for obesity 14.

States may also require a diagnosis code from ICD-10 E66.01 (morbid obesity due to excess calories) or E66.09 (other obesity due to excess calories) to process the PA request.

Step Therapy Requirements for Retatrutide on Medicaid

Most state Medicaid programs enforce step therapy, sometimes called "fail-first" protocols, for newer or higher-cost medications. For GLP-1 agonists, this typically means demonstrating inadequate response or intolerance to at least one lower-cost agent before approving a newer drug.

Common step therapy sequences in current Medicaid formularies require trial and failure of:

1. Lifestyle modification alone (3 to 6 months)
2. Generic phentermine or phentermine-topiramate (if not contraindicated)
3. An older GLP-1 agonist such as liraglutide 3.0 mg (Saxenda)

Only after documented failure of these steps would a state Medicaid program consider approving a newer agent. Tirzepatide (Zepbound), which demonstrated 22.5% weight loss at 72 weeks in the SURMOUNT-1 trial (N=2,539) 15, still faces step therapy hurdles in many states despite FDA approval.

Retatrutide's triple-agonist mechanism may eventually allow prescribers to argue for medical necessity without step therapy, particularly for patients with concurrent metabolic dysfunction-associated steatotic liver disease (MASLD). In the phase 2 trial, the 12 mg retatrutide dose produced a mean 81% relative reduction in liver fat in participants with fatty liver disease at baseline 16. The American Association for the Study of Liver Diseases (AASLD) practice guidance identifies weight loss of ≥ 10% as likely needed to resolve steatohepatitis and improve fibrosis 17.

How to Appeal a State Medicaid Denial of Retatrutide

Every state Medicaid program is required by federal law to provide a fair-hearing process when a claim is denied 18. The process follows a consistent structure across states, though timelines and documentation requirements differ.

Step 1: Request the denial in writing. Contact your state Medicaid office or managed care organization (MCO) and request a written Notice of Action. This document specifies the reason for denial and your appeal rights. Federal rules require the notice within specific timeframes, typically 10 business days.

Step 2: File an internal appeal. Most states require an internal appeal with the MCO before you can request a state fair hearing. Include the prescriber's letter of medical necessity, relevant clinical data (BMI, A1C, liver imaging if applicable), and documentation of step therapy failures.

Step 3: Cite clinical evidence. The Jastreboff et al. phase 2 data showing up to 24.2% weight loss at 48 weeks is the strongest currently published evidence for retatrutide 19. For patients with type 2 diabetes, reference the ADA Standards of Care, which endorse GLP-1 receptor agonists for glucose lowering and cardiovascular risk reduction 20.

Step 4: Request a state fair hearing. If the internal appeal fails, you have the right to an administrative hearing before an independent judge. Time limits for requesting this hearing vary by state but are typically 30 to 90 days from the denial notice.

Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital, has stated: "The appeal process can feel daunting, but well-documented medical necessity letters that reference guideline-concordant care significantly improve approval rates" 21.

Can You Use a Manufacturer Savings Card with Medicaid?

No. Federal anti-kickback statutes prohibit the use of manufacturer co-pay cards, savings cards, or coupons for prescriptions covered by Medicaid, Medicare, TRICARE, or any other federally funded program 22. This rule applies regardless of whether Medicaid is the primary or secondary payer.

Eli Lilly does offer patient assistance programs (PAPs) for some of its approved medications. The Lilly Cares Foundation, for example, provides free medications to qualifying uninsured patients. Once retatrutide receives approval, a similar program may become available, but PAP eligibility typically excludes patients with Medicaid coverage.

For patients whose Medicaid does not cover anti-obesity medications, the only legal options are:

• Clinical trial enrollment (search at clinicaltrials.gov)
• State-specific exceptions through the fair-hearing process
• Out-of-pocket payment at the eventual retail price (not yet established)
• Transitioning to a commercial plan during open enrollment if eligible

Retatrutide's Ongoing Phase 3 Program and Approval Timeline

The TRIUMPH clinical trial program includes multiple phase 3 studies evaluating retatrutide for obesity, type 2 diabetes, and MASLD. Eli Lilly has stated publicly that these trials are expected to read out results in 2025 and 2026 23. An FDA approval could follow 10 to 12 months after submission of a complete NDA, assuming no major safety signals emerge.

Once approved, the path to Medicaid coverage would depend on several factors:

• Indication approved. If retatrutide receives a type 2 diabetes indication, Medicaid coverage would be near-automatic under the Medicaid Drug Rebate Program. An obesity-only indication would leave coverage at each state's discretion.
• Rebate negotiations. Drug manufacturers negotiate rebates with state Medicaid programs through the federal Medicaid Drug Rebate Program. The Congressional Budget Office projected that the Inflation Reduction Act's provisions could influence rebate dynamics for new high-cost specialty drugs 24.
• State budget considerations. The CDC reports that 41.9% of U.S. adults meet criteria for obesity 25. Covering a new anti-obesity medication for even a fraction of eligible Medicaid beneficiaries represents a substantial budget item.

The American Gastroenterological Association and AASLD have both noted the potential of GLP-1 and multi-agonist therapies for MASLD, a condition affecting an estimated 30% of U.S. adults 26. A MASLD indication for retatrutide could open a different coverage pathway, as liver disease treatments have historically faced fewer Medicaid exclusions than weight-loss drugs.

What Formulary Tier Retatrutide Might Occupy

Medicaid formularies typically organize drugs into three to five tiers. Preferred generics sit on Tier 1, preferred brands on Tier 2, and non-preferred or specialty drugs on Tier 3 or higher. GLP-1 receptor agonists for diabetes generally land on Tier 2 (preferred brand) or Tier 3 (non-preferred brand) depending on state-level rebate agreements 27.

For anti-obesity indications, states that do cover these drugs almost universally place them on non-preferred or specialty tiers. This means higher cost-sharing (though Medicaid co-pays are capped at nominal amounts for most beneficiaries) and mandatory PA.

Retatrutide's triple-agonist mechanism, which produced weight loss exceeding that seen in tirzepatide's SURMOUNT program, may warrant specialty tier placement. In the phase 2 trial, the highest dose group achieved a mean 24.2% body-weight reduction, compared with tirzepatide's 22.5% in SURMOUNT-1 28. If the phase 3 data confirm or exceed these results, payers may face increasing pressure from the Endocrine Society and ADA guidelines recommending these agents as first-line treatment 29.

Monitoring State-Level Policy Changes

State Medicaid formulary decisions are published in each state's Preferred Drug List (PDL), typically updated quarterly. The Centers for Medicare & Medicaid Services (CMS) maintains a publicly accessible database of state Medicaid program contacts and formulary resources 30.

Patients and prescribers tracking retatrutide coverage should:

• Check their state's PDL at least quarterly after FDA approval
• Monitor Drug Utilization Review (DUR) board meeting minutes, which are public records
• Contact their state Medicaid pharmacy director for advance notice of formulary changes
• Work with patient advocacy organizations like the Obesity Action Coalition for real-time legislative tracking

The 2024 Endocrine Society guideline explicitly calls for reducing insurance barriers to evidence-based obesity pharmacotherapy and recommends that clinicians advocate through payer appeals and policy engagement 31.

As of this writing, 14 state Medicaid programs have introduced or expanded GLP-1 coverage for obesity since 2023. North Carolina, for instance, added semaglutide 2.4 mg to its Medicaid PDL in 2024 after a DUR board review of STEP trial data showing sustained weight loss and cardiovascular benefit in the SELECT trial (N=17,604), which demonstrated a 20% reduction in major adverse cardiovascular events 32.